MALAT1 and triple-negative breast carcinoma: Targeting MALAT1 in association with PARPi: in triple negative breast cancer, lncRNAs can be used to cluster the patients in subgroups, while five transcripts of the MALAT1 gene are specifically upregulated in resistant patients and are involved in resistance to chemotherapy [148, 151–153, 211].